2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl bromide

We are 2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl bromide CAS:160969-00-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl bromide
CAS.NO:160969-00-6
Synonyms:2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl bromide
1-(2-Bromo-ethoxy)-2-(2,2,2,trifluro ethoxy)benzene
1-(2-Bromoethoxy)-2-(2,2,2-trifluoroethoxy)benzene
 
Physical and Chemical Properties:
Density 1.5±0.1 g/cm3
Boiling Point 273.6±40.0 °C at 760 mmHg
Molecular Formula C10H10BrF3O2
Molecular Weight 299.084
Flash Point 148.0±11.6 °C
 
Specification:
Appearance:Colourless to yellow liquid
Assay:≥95.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Silodosin(CAS:160970-54-7).

2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl bromide


Related News: The policy-oriented emphasis on the medical and pharmaceutical industries and the direct support for the chemical raw material pharmaceutical industry have created a good political environment for the development of related enterprises and laid the foundation for the rapid development of the chemical raw material pharmaceutical industry. The good development prospects of the chemical raw material pharmaceutical industry will be passed directly to the upstream raw material industry, which will help stimulate the demand for the pharmaceutical intermediate market.Methyl 2-bromo-3-methylbutanoate CAS:26330-51-8 In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.2-chloro-4,6-di(naphthalen-1-yl)-1,3,5-triazine CAS:78941-32-9 In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.(5-formylfuran-2-yl)boronic acid Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.

Related Products
Product Name
1-Hydroxycyclohexyl Phenyl Ketone View Details
4-Methylpiperidine View Details
Barium Selenite View Details
10-Fluorodecan-1-ol manufacturer FMOC-S-trityl-L-cysteine manufacturer Optical Brightening Agent OB manufacturer (2S)-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]propanoic acid manufacturer 2-Bromo-6-fluorotoluene manufacturer